Shantou Real Estate Hexin Co., Ltd. acquired Shantou Tai'an Investment Development Co., Ltd. from Guangdong Taiantang Pharmaceutical Co., Ltd. for CNY 240 million.
December 12, 2022
Share
Shantou Real Estate Hexin Co., Ltd. agreed to acquire Shantou Tai'an Investment Development Co., Ltd. from Guangdong Taiantang Pharmaceutical Co., Ltd. (SZSE:002433) for CNY 240 million on December 13, 2021. At termination, the party at fault shall still pay 10% of the total transaction price as agreed in this agreement. The deal is subject to approval from Guangdong Taiantang Pharmaceutical Co., Ltd. (SZSE:002433) board. As of December 13, 2021 Guangdong Taiantang Pharmaceutical Co., Ltd. (SZSE:002433) board approved the deal.
Shantou Real Estate Hexin Co., Ltd. completed the acquisition of Shantou Tai'an Investment Development Co., Ltd. from Guangdong Taiantang Pharmaceutical Co., Ltd. (SZSE:002433) on December 13, 2022 which is an estimated closing date.
Guangdong Taiantang Pharmaceutical Co Ltd is a company mainly engaged in the manufacturing of Chinese patent medicines and the primary processing of Chinese medicinal materials. The Company operates five segments. Chinese Patent Medicines Manufacturing Business segment is mainly responsible for the production and wholesale of Pibao cream, Qilin pill, Xinbao pill, Xinxin pill, Tongqiao Yixin pill, etc. Primary Processing Business segment of the traditional Chinese medicine materials is mainly responsible for planting, primary processing and sales of the ginseng and traditional Chinese medicine materials. Drug Wholesale and Retail Business segment is mainly responsible for the wholesale and retail of drugs and medical devices. Health Industry Development and Products Sales segment is mainly responsible for the development and sales of health concept real estate products. Medical Services segment is mainly responsible for the in-depth development of medical and elderly care services.
GUANGDONG TAIANTANG PHARMACEUTICAL CO., LTD. 
